Country: Indoneżja
Lingwa: Indoneżjan
Sors: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
MESALAZINE
DARYA-VARIA LABORATORIA TBK - Indonesia
MESALAZINE
500 MG
SUPPOSITORIA
DUS, 6 STRIP @ 5 SUPPOSITORIA
DR. FALK PHARMA GMBH - Germany
2017-01-31
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SALOFALK ® Mesalazine (5-aminosalicylic acid) Suppositories 500 mg 2 COMPOSITION Each Salofalk suppository contains 500 mg mesalazine. Excipient with known effect: cetyl alcohol For the full list of excipients, see section “Pharmaceutical particulars” further down. 3 DOSAGE FORM Suppository White to cream-coloured torpedo shaped suppositories, even consistency and undamaged smooth surface 4 CLINICAL PARTICULARS 4.1 INDICATIONS Treatment of acute episodes of mildly to moderately active ulcerative proctitis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ _ Posology Adults and the elderly: One Salofalk ® 500 suppository three times daily (equivalent to 1500 mg mesalazine daily) inserted into the rectum, according to the individual clinical requirement. The dosage should be adjusted to suit the progress of the condition. Do not discontinue treatment suddenly. Method of administration Rectal 4.3 CONTRAINDICATIONS Salofalk suppositories are contraindicated in cases of - Severe impairment of renal or hepatic function. - Hypersensitivity to the active substance, salicylates or to any of the excipients listed in section “Pharmaceutical Particulars”. - Gastric and duodenal ulcers. - Haemorrhagic diathesis (presdisposition to bleeding). DISETUJUI OLEH BPOM: 01/06/2023 ID REG: EREG10008712100119 Salofalk® 500 suppositories should not be used to treat infants and small children because of insufficient experience with this age group. 4.4 WARNINGS AND PRECAUTIONS Blood tests (differential blood count; liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip-sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to three tests at intervals of 4 weeks. If the findings are normal, follow-up tests should be carried out every 3 months. If additional symptoms occur, these te Aqra d-dokument sħiħ